New Partners Hunt Breakthroughs for Kids With Rare Brain Disorders
Angelini Pharma and Quiver Bioscience have joined forces to hunt for new medicines that could help children suffering from hard‑to‑treat genetic epilepsies. The partnership blends Angelini’s deep experience in brain drugs with Quiver’s cutting‑edge AI tools and human neuron models.
Deal Highlights
- Multi‑year contract: Quiver receives an upfront payment plus milestone bonuses.
- Data rights: Angelini can use all data from joint studies.
- Potential upside: Quiver could earn up to $120 million if Angelini develops a drug based on their discoveries.
Focus Area
The collaboration targets Developmental and Epileptic Encephalopathies—rare childhood diseases that cause severe seizures and learning problems. While some treatments exist, many patients still need better options because the exact mechanisms by which gene mutations damage brain cells remain unclear.
How Quiver’s Tech Works
- Engineered human neurons
- Single‑cell recordings
- Machine learning
These tools map how specific gene changes alter brain cell behavior, linking functional changes to underlying biology. The goal is to spot new therapeutic targets that could work across multiple disorders.
Statements from Leadership
- Angelini’s Chief Scientific Officer: “The collaboration should generate a wealth of data far richer than what has been seen before in this field.”
- Quiver’s CEO: “The partnership will translate our experimental findings into real medicines for a condition that urgently needs innovation.”
Context and Future Plans
This agreement follows a series of other deals Angelini has made in the past two years, expanding its reach and sharpening its focus on brain health. Both companies view the partnership as a step toward expanding their global presence and adding promising new candidates to their pipelines.
